Respiratory Syncytial Virus Market to Reach USD 4.54 Billion by 2033 as Global Uptake of Next-Generation Vaccines & Monoclonal Antibodies Accelerates
Comunicato Precedente
Comunicato Successivo
Download PDF Brochure: https://www.datamintelligence.com/download-sample/respiratory-syncytial-virus-market
Browse in-depth TOC on "Respiratory Syncytial Virus (RSV) Market"
62 – Tables
57 – Figures
159 – Pages
A New Vaccination Era: Why the RSV Market Is Scaling Faster Than Ever Before
In the past two years, RSV has shifted from being an overlooked seasonal virus to one of the most aggressively targeted infectious diseases in the pharmaceutical pipeline. Major drivers shaping the market include:
1. First-Ever Adult RSV Vaccines Transform the Market
GSK's Arexvy and Pfizer's Abrysvo-approved for adults ≥60 and pregnant women-have created a multi-billion-dollar opportunity in elder immunization and maternal immunization.
2. Breakthrough Monoclonal Antibody Prophylaxis for Infants
Nirsevimab (Sanofi/AstraZeneca) is disrupting infant protection with only one dose per RSV season, expanding coverage by 5x compared with earlier products like palivizumab.
3. Escalating RSV Hospitalizations Across Age Groups
An aging demographic, rising comorbidities, and viral seasonality shifts have increased hospital RSV admissions by 22% YoY in the U.S. and several Asian nations.
4. Pipeline Acceleration in Antivirals
Multiple oral and inhaled antiviral candidates from global pharma companies aim to reduce severe RSV outcomes across all age groups.
Combined, these factors position RSV as the fastest-growing respiratory infection market globally-second only to influenza.
Market Segmentation
By Drug Class (Vaccines, Monoclonal Antibodies, Antivirals)
Vaccines
Vaccines represented the largest segment in 2024, contributing 56% (USD 1.09 billion) of global revenue. Adult RSV vaccination and maternal immunization programs are expanding rapidly across the U.S., Japan, Europe, and select Asia-Pacific markets.
Monoclonal Antibodies
Monoclonal antibodies accounted for 33% (USD 644 million) of the market. Nirsevimab's high-efficacy, single-dose seasonal protection has dramatically expanded infant immunization eligibility and uptake.
Antivirals
Antivirals held 11% (USD 214 million). Oral and inhaled antivirals remain essential for high-risk adults and immunocompromised patients, with strong pipeline potential expected to increase segment share by 2030.
By Age Group (Infants & Children, Adults, Geriatric)
Infants & Children
This segment accounted for 48% (USD 936 million) of 2024 global revenue.
Pediatric RSV remains the primary disease burden, with infants <6 months making up the majority of hospital admissions and ICU stays.
Adults
Adults represented 29% (USD 566 million), driven by new RSV vaccine approvals for older adults and immunocompromised populations.
Geriatric
The geriatric segment (aged ≥65) accounted for 23% (USD 448 million), reflecting high susceptibility to lower respiratory illnesses, severe complications, and hospitalization.
By Distribution Channel (Hospital Pharmacies, Retail Pharmacies)
Hospital Pharmacies
Hospital pharmacies captured 62% (USD 1.21 billion) of revenue as severe RSV cases-including infants and the elderly-are managed through hospital-based vaccination, monoclonal antibody programs, and inpatient antiviral administration.
Retail Pharmacies
Retail pharmacies represented 38% (USD 741 million), largely driven by adult RSV vaccinations delivered through community pharmacies, primary care clinics, and maternal immunization providers.
Buy This Report with Year-End Offer (Buy 1 report: Get 30% OFF | Buy 2 Reports: Get 50% OFF each! Limited time offer): https://www.datamintelligence.com/buy-now-page?report=respiratory-syncytial-virus-market
Regional Analysis
United States: The World's Largest RSV Market
The U.S. accounted for 44% (USD 858 million) of global RSV revenues in 2024.
Key U.S. Market Indicators
The U.S. market is projected to exceed USD 2.0 billion by 2033, driven by nationwide infant immunization programs and rapid pharmacy-based vaccination expansion.
Japan: Rising Adoption of Adult Vaccines & Infant Antibodies
Japan accounted for 7% (USD 136 million) of global revenues in 2024.
Japan Market Highlights
Japan is projected to reach USD 360+ million by 2033 as adult vaccine coverage accelerates.
Buy This Report with Year-End Offer (Buy 1 report: Get 30% OFF | Buy 2 reports: Get 50% OFF each! Limited time offer): https://www.datamintelligence.com/buy-now-page?report=respiratory-syncytial-virus-market
Competitive Landscape
Pfizer Inc.
GSK plc
Moderna, Inc.
AstraZeneca plc
Sanofi S.A.
Merck & Co., Inc.
The Future of RSV Therapeutics: What will Reshape the Market Through 2033
The RSV therapeutics landscape is evolving faster than any other respiratory market. Key developments expected by 2033 include:
Related Report:
About DataM Intelligence
DataM Intelligence is a renowned provider of market research, delivering deep insights through pricing analysis, market share breakdowns, and competitive intelligence. The company specializes in strategic reports that guide businesses in high-growth sectors such as nutraceuticals and AI-driven health innovations.
To find out more, visit https://www.datamintelligence.com/ or follow us on Twitter, LinkedIn, and Facebook.
Contact:
Sai Kiran
DataM Intelligence 4market Research LLP
Ground floor, DSL Abacus IT Park, Industrial Development Area
Uppal, Hyderabad, Telangana 500039
USA: +1 877-441-4866
Email: Sai.k@datamintelligence.com
Logo: https://mma.prnewswire.com/media/1858619/3573087/DataM_Intelligence_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/respiratory-syncytial-virus-market-to-reach-usd-4-54-billion-by-2033-as-global-uptake-of-next-generation-vaccines--monoclonal-antibodies-accelerates-302629123.html
Ufficio Stampa
PR Newswire (Leggi tutti i comunicati)
209 - 215 Blackfriars Road
LONDON United Kingdom
